A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Recruiting	Phase 1	2023-11-01		NCT03110822

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Incyte Corporation	153
Oncotherapeutics	4

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
California Cancer Associates for Research & Excellence (cCARE)	Encinitas	United States	1
Cancer Specialists, LLC	Jacksonville	United States	3
Compassionate Care Research Group, Inc.	Fountain Valley	United States	2
Comprehensive Blood and Cancer Center	Bakersfield	United States	1
Global Oncology, Inc.	Alhambra	United States	1
James R. Berenson M.D. Inc.	West Hollywood	United States	1
Millennium Oncology Research Clinic	Pembroke Pines	United States	1
Northwest Medical Specialists, PPLC	Tacoma	United States	1
Pacific Cancer Care	Monterey	United States	13
Regional Cancer Care Associates (RCCA) MD, LLC	Bethesda	United States	1
Robert A. Moss, M.D., F.A.C.P., Inc.	Fountain Valley	United States	1
Sansum Clinic- Ridley-Tree Cancer Center	Santa Barbara	United States	1
Wellness Oncology and Hematology	West Hills	United States	1